Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of smart adherence technology for Orkambi adherence in cystic fibrosis
2016-004996-33Phase 4Terminated
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lumacaftor + ivacaftor in cystic fibrosis (CF) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Mean percentage adherence to lumacaftor/ivacaftor treatment over 48 weeks. Started Mar 2017; status: terminated.
02
Drugs
lumacaftor + ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2016-004996-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004996-33.